Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Extracellular Vesicles Isolated from Familial Alzheimer's Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain.

Aulston B, Liu Q, Mante M, Florio J, Rissman RA, Yuan SH.

J Alzheimers Dis. 2019 Oct 3. doi: 10.3233/JAD-190656. [Epub ahead of print]

PMID:
31594233
2.

Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.

Mandler M, Rockenstein E, Overk C, Mante M, Florio J, Adame A, Kim C, Santic R, Schneeberger A, Mattner F, Schmidhuber S, Galabova G, Spencer B, Masliah E, Rissman RA.

Alzheimers Dement. 2019 Sep;15(9):1133-1148. doi: 10.1016/j.jalz.2019.02.002. Epub 2019 Aug 1.

PMID:
31378574
3.

Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Spencer B, Trinh I, Rockenstein E, Mante M, Florio J, Adame A, El-Agnaf OMA, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5.

PMID:
30849508
4.

Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies.

Hassen GW, Kesner L, Stracher A, Shulman A, Rockenstein E, Mante M, Adame A, Overk C, Rissman RA, Masliah E.

Sci Rep. 2018 Dec 27;8(1):18083. doi: 10.1038/s41598-018-35729-1.

5.

LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation.

Bae EJ, Kim DK, Kim C, Mante M, Adame A, Rockenstein E, Ulusoy A, Klinkenberg M, Jeong GR, Bae JR, Lee C, Lee HJ, Lee BD, Di Monte DA, Masliah E, Lee SJ.

Nat Commun. 2018 Aug 27;9(1):3465. doi: 10.1038/s41467-018-05958-z.

6.

Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.

Kim C, Spencer B, Rockenstein E, Yamakado H, Mante M, Adame A, Fields JA, Masliah D, Iba M, Lee HJ, Rissman RA, Lee SJ, Masliah E.

Mol Neurodegener. 2018 Aug 9;13(1):43. doi: 10.1186/s13024-018-0276-2.

7.

Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders.

Spencer B, Brüschweiler S, Sealey-Cardona M, Rockenstein E, Adame A, Florio J, Mante M, Trinh I, Rissman RA, Konrat R, Masliah E.

Acta Neuropathol. 2018 Jul;136(1):69-87. doi: 10.1007/s00401-018-1869-0. Epub 2018 Jun 14.

8.

Increased Vulnerability of the Hippocampus in Transgenic Mice Overexpressing APP and Triple Repeat Tau.

Arner A, Rockenstein E, Mante M, Florio J, Masliah D, Salehi B, Adame A, Overk C, Masliah E, Rissman RA.

J Alzheimers Dis. 2018;61(3):1201-1219. doi: 10.3233/JAD-170388.

9.

Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.

Rockenstein E, Ostroff G, Dikengil F, Rus F, Mante M, Florio J, Adame A, Trinh I, Kim C, Overk C, Masliah E, Rissman RA.

J Neurosci. 2018 Jan 24;38(4):1000-1014. doi: 10.1523/JNEUROSCI.1170-17.2017. Epub 2017 Dec 15.

10.

MicroRNA-101 Modulates Autophagy and Oligodendroglial Alpha-Synuclein Accumulation in Multiple System Atrophy.

Valera E, Spencer B, Mott J, Trejo M, Adame A, Mante M, Rockenstein E, Troncoso JC, Beach TG, Masliah E, Desplats P.

Front Mol Neurosci. 2017 Oct 17;10:329. doi: 10.3389/fnmol.2017.00329. eCollection 2017.

11.

Brain-derived exosomes from dementia with Lewy bodies propagate α-synuclein pathology.

Ngolab J, Trinh I, Rockenstein E, Mante M, Florio J, Trejo M, Masliah D, Adame A, Masliah E, Rissman RA.

Acta Neuropathol Commun. 2017 Jun 9;5(1):46. doi: 10.1186/s40478-017-0445-5.

12.

Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.

El-Agnaf O, Overk C, Rockenstein E, Mante M, Florio J, Adame A, Vaikath N, Majbour N, Lee SJ, Kim C, Masliah E, Rissman RA.

Neurobiol Dis. 2017 Aug;104:85-96. doi: 10.1016/j.nbd.2017.05.002. Epub 2017 May 2.

13.

Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.

Spencer B, Valera E, Rockenstein E, Overk C, Mante M, Adame A, Zago W, Seubert P, Barbour R, Schenk D, Games D, Rissman RA, Masliah E.

Acta Neuropathol Commun. 2017 Jan 13;5(1):7. doi: 10.1186/s40478-016-0410-8.

14.

Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy.

Valera E, Spencer B, Fields JA, Trinh I, Adame A, Mante M, Rockenstein E, Desplats P, Masliah E.

Acta Neuropathol Commun. 2017 Jan 5;5(1):2. doi: 10.1186/s40478-016-0409-1.

15.

α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.

Spencer B, Williams S, Rockenstein E, Valera E, Xin W, Mante M, Florio J, Adame A, Masliah E, Sierks MR.

Ann Clin Transl Neurol. 2016 Jun 16;3(8):588-606. doi: 10.1002/acn3.321. eCollection 2016 Aug.

16.

Neuregulin 1 improves cognitive deficits and neuropathology in an Alzheimer's disease model.

Xu J, de Winter F, Farrokhi C, Rockenstein E, Mante M, Adame A, Cook J, Jin X, Masliah E, Lee KF.

Sci Rep. 2016 Aug 25;6:31692. doi: 10.1038/srep31692.

17.

Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA, Wu C, Mante M, Adame A, Florio J, Rockenstein E, Masliah E.

J Neurosci. 2016 Jul 27;36(30):7971-84. doi: 10.1523/JNEUROSCI.0775-16.2016.

18.

Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.

Price DL, Rockenstein E, Mante M, Adame A, Overk C, Spencer B, Duong-Polk KX, Bonhaus D, Lindsey J, Masliah E.

Sci Rep. 2016 Jul 8;6:29523. doi: 10.1038/srep29523.

19.

Neuroprotective effects of the immunomodulatory drug FK506 in a model of HIV1-gp120 neurotoxicity.

Fields JA, Overk C, Adame A, Florio J, Mante M, Pineda A, Desplats P, Rockenstein E, Achim C, Masliah E.

J Neuroinflammation. 2016 May 24;13(1):120. doi: 10.1186/s12974-016-0585-8.

20.

Hypoestoxide reduces neuroinflammation and α-synuclein accumulation in a mouse model of Parkinson's disease.

Kim C, Ojo-Amaize E, Spencer B, Rockenstein E, Mante M, Desplats P, Wrasidlo W, Adame A, Nchekwube E, Oyemade O, Okogun J, Chan M, Cottam H, Masliah E.

J Neuroinflammation. 2015 Dec 18;12:236. doi: 10.1186/s12974-015-0455-9.

21.

Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies.

Rockenstein E, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E.

BMC Neurosci. 2015 Nov 26;16:85. doi: 10.1186/s12868-015-0218-7.

22.

Appoptosin-Mediated Caspase Cleavage of Tau Contributes to Progressive Supranuclear Palsy Pathogenesis.

Zhao Y, Tseng IC, Heyser CJ, Rockenstein E, Mante M, Adame A, Zheng Q, Huang T, Wang X, Arslan PE, Chakrabarty P, Wu C, Bu G, Mobley WC, Zhang YW, St George-Hyslop P, Masliah E, Fraser P, Xu H.

Neuron. 2015 Sep 2;87(5):963-75. doi: 10.1016/j.neuron.2015.08.020.

23.

Neuro-peptide treatment with Cerebrolysin improves the survival of neural stem cell grafts in an APP transgenic model of Alzheimer disease.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Masliah E.

Stem Cell Res. 2015 Jul;15(1):54-67. doi: 10.1016/j.scr.2015.04.008. Epub 2015 May 9.

24.

Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.

Valera E, Mante M, Anderson S, Rockenstein E, Masliah E.

J Neuroinflammation. 2015 May 14;12:93. doi: 10.1186/s12974-015-0320-x.

25.

Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy.

Mandler M, Valera E, Rockenstein E, Mante M, Weninger H, Patrick C, Adame A, Schmidhuber S, Santic R, Schneeberger A, Schmidt W, Mattner F, Masliah E.

Mol Neurodegener. 2015 Mar 19;10:10. doi: 10.1186/s13024-015-0008-9.

26.

A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.

Rockenstein E, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Bisquert A, Trejo-Morales M, Spencer B, Masliah E.

PLoS One. 2015 Mar 24;10(3):e0121570. doi: 10.1371/journal.pone.0121570. eCollection 2015.

27.

Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease.

Rockenstein E, Desplats P, Ubhi K, Mante M, Florio J, Adame A, Winter S, Brandstaetter H, Meier D, Moessler H, Masliah E.

J Exp Neurosci. 2016 Jul 7;9(Suppl 2):131-40. doi: 10.4137/JEN.S25521. eCollection 2015.

28.

Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease.

Eleuteri S, Di Giovanni S, Rockenstein E, Mante M, Adame A, Trejo M, Wrasidlo W, Wu F, Fraering PC, Masliah E, Lashuel HA.

Neurobiol Dis. 2015 Feb;74:144-57. doi: 10.1016/j.nbd.2014.08.017. Epub 2014 Aug 28.

29.

Cerebrolysin™ efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure.

Rockenstein E, Ubhi K, Trejo M, Mante M, Patrick C, Adame A, Novak P, Jech M, Doppler E, Moessler H, Masliah E.

BMC Neurosci. 2014 Jul 21;15:90. doi: 10.1186/1471-2202-15-90.

30.

Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sacayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E.

J Neurosci. 2014 Jul 9;34(28):9441-54. doi: 10.1523/JNEUROSCI.5314-13.2014.

31.

Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo.

Rockenstein E, Nuber S, Overk CR, Ubhi K, Mante M, Patrick C, Adame A, Trejo-Morales M, Gerez J, Picotti P, Jensen PH, Campioni S, Riek R, Winkler J, Gage FH, Winner B, Masliah E.

Brain. 2014 May;137(Pt 5):1496-513. doi: 10.1093/brain/awu057. Epub 2014 Mar 24.

32.

Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Nuber S, Tadros D, Fields J, Overk CR, Ettle B, Kosberg K, Mante M, Rockenstein E, Trejo M, Masliah E.

Acta Neuropathol. 2014 Apr;127(4):477-94. doi: 10.1007/s00401-014-1255-5. Epub 2014 Feb 8.

33.

Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy.

Valera E, Ubhi K, Mante M, Rockenstein E, Masliah E.

Glia. 2014 Feb;62(2):317-37. doi: 10.1002/glia.22610. Epub 2013 Dec 6.

34.

Widespread microRNA dysregulation in multiple system atrophy - disease-related alteration in miR-96.

Ubhi K, Rockenstein E, Kragh C, Inglis C, Spencer B, Michael S, Mante M, Adame A, Galasko D, Masliah E.

Eur J Neurosci. 2014 Mar;39(6):1026-41. doi: 10.1111/ejn.12444. Epub 2013 Dec 5.

35.

S-Nitrosylation of parkin as a novel regulator of p53-mediated neuronal cell death in sporadic Parkinson's disease.

Sunico CR, Nakamura T, Rockenstein E, Mante M, Adame A, Chan SF, Newmeyer TF, Masliah E, Nakanishi N, Lipton SA.

Mol Neurodegener. 2013 Aug 28;8:29. doi: 10.1186/1750-1326-8-29.

36.

TOM40 mediates mitochondrial dysfunction induced by α-synuclein accumulation in Parkinson's disease.

Bender A, Desplats P, Spencer B, Rockenstein E, Adame A, Elstner M, Laub C, Mueller S, Koob AO, Mante M, Pham E, Klopstock T, Masliah E.

PLoS One. 2013 Apr 23;8(4):e62277. doi: 10.1371/journal.pone.0062277. Print 2013.

37.

Age-dependent molecular alterations in the autophagy pathway in HIVE patients and in a gp120 tg mouse model: reversal with beclin-1 gene transfer.

Fields J, Dumaop W, Rockenstein E, Mante M, Spencer B, Grant I, Ellis R, Letendre S, Patrick C, Adame A, Masliah E.

J Neurovirol. 2013 Feb;19(1):89-101. doi: 10.1007/s13365-012-0145-7. Epub 2013 Jan 24.

38.

Role of α-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus.

Winner B, Regensburger M, Schreglmann S, Boyer L, Prots I, Rockenstein E, Mante M, Zhao C, Winkler J, Masliah E, Gage FH.

J Neurosci. 2012 Nov 21;32(47):16906-16. doi: 10.1523/JNEUROSCI.2723-12.2012.

39.

Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer's disease.

Ubhi K, Rockenstein E, Vazquez-Roque R, Mante M, Inglis C, Patrick C, Adame A, Fahnestock M, Doppler E, Novak P, Moessler H, Masliah E.

J Neurosci Res. 2013 Feb;91(2):167-77. doi: 10.1002/jnr.23142. Epub 2012 Nov 14.

PMID:
23152192
40.

Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease.

Desplats P, Patel P, Kosberg K, Mante M, Patrick C, Rockenstein E, Fujita M, Hashimoto M, Masliah E.

Mol Neurodegener. 2012 Sep 28;7:49. doi: 10.1186/1750-1326-7-49.

41.

Neuronal to oligodendroglial α-synuclein redistribution in a double transgenic model of multiple system atrophy.

Rockenstein E, Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Masliah E.

Neuroreport. 2012 Mar 7;23(4):259-64. doi: 10.1097/WNR.0b013e3283509842.

42.

Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, Rockenstein E, May V, Winkler J, Masliah E.

Exp Neurol. 2012 Apr;234(2):405-16. doi: 10.1016/j.expneurol.2012.01.008. Epub 2012 Jan 16.

43.

Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model.

Kohl Z, Winner B, Ubhi K, Rockenstein E, Mante M, Münch M, Barlow C, Carter T, Masliah E, Winkler J.

Eur J Neurosci. 2012 Jan;35(1):10-9. doi: 10.1111/j.1460-9568.2011.07933.x.

44.

Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AβPP transgenic mice.

Rockenstein E, Ubhi K, Doppler E, Novak P, Moessler H, Li B, Blanchard J, Grundke-Iqbal I, Iqbal K, Mante M, Adame A, Crews L, Masliah E.

J Alzheimers Dis. 2011;27(4):743-52. doi: 10.3233/JAD-2011-110914.

45.

Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer's disease.

Rockenstein E, Ubhi K, Pham E, Michael S, Doppler E, Novak P, Inglis C, Mante M, Adame A, Alvarez XA, Moessler H, Masliah E.

J Neurosci Res. 2011 Nov;89(11):1812-21. doi: 10.1002/jnr.22712. Epub 2011 Jul 25.

46.

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.

Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D.

PLoS One. 2011 Apr 29;6(4):e19338. doi: 10.1371/journal.pone.0019338.

47.

Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Whitney K, Masliah E.

J Neurosci. 2010 May 5;30(18):6236-46. doi: 10.1523/JNEUROSCI.0567-10.2010.

48.

Genetic deletion of Nogo/Rtn4 ameliorates behavioral and neuropathological outcomes in amyloid precursor protein transgenic mice.

Masliah E, Xie F, Dayan S, Rockenstein E, Mante M, Adame A, Patrick CM, Chan AF, Zheng B.

Neuroscience. 2010 Aug 11;169(1):488-94. doi: 10.1016/j.neuroscience.2010.04.045. Epub 2010 Apr 28.

49.

Alpha-synuclein deficient mice are resistant to toxin-induced multiple system atrophy.

Ubhi K, Rockenstein E, Mante M, Inglis C, Adame A, Patrick C, Masliah E.

Neuroreport. 2010 Apr 21;21(6):457-62. doi: 10.1097/WNR.0b013e328338ba6b.

50.

Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies.

Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E.

Exp Neurol. 2010 Feb;221(2):267-74. doi: 10.1016/j.expneurol.2009.11.015. Epub 2009 Nov 26.

Supplemental Content

Support Center